Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $6.2 million.

  • ARS Pharmaceuticals' Other Working Capital Changes fell 312.10% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 742.90%. This contributed to the annual value of $6.2 million for FY2024, which is 297.35% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Other Working Capital Changes stood at $6.2 million for FY2024, which was up 297.35% from -$3.1 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Other Working Capital Changes high stood at $6.2 million for FY2024, and its period low was -$3.1 million during FY2023.
  • In the last 3 years, ARS Pharmaceuticals' Other Working Capital Changes had a median value of -$1.3 million in 2022 and averaged $579,333.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Other Working Capital Changes plummeted by 170.92% in 2021, and later spiked by 297.35% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Other Working Capital Changes (Yearly) stood at $3.5 million in 2020, then slumped by 170.92% to -$2.5 million in 2021, then surged by 47.51% to -$1.3 million in 2022, then tumbled by 138.37% to -$3.1 million in 2023, then spiked by 297.35% to $6.2 million in 2024.